Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033762015> ?p ?o ?g. }
- W3033762015 endingPage "2030" @default.
- W3033762015 startingPage "2019" @default.
- W3033762015 abstract "The goal of this research is the identification of new treatments for neuropathic pain. We characterized the GABAergic system of immortalized mouse and human microglia using electrophysiology and qRT-PCR. Cells from both species exhibited membrane current changes in response to γ-aminobutyric acid, with an EC50 of 260 and 1940 nM, respectively. Human microglia expressed high levels of the γ-aminobutyric acid type A receptor (GABAAR) α3 subunit, which can assemble with β1 and γ2/δ subunits to form functional GABAARs. Mouse microglia contained α2, α3, and α5, in addition to β1–3, γ1–2, and δ, mRNA, enabling a more diverse array of GABAARs than human microglia. Benzodiazepines are well-established modulators of GABAAR activity, prompting a screen of a library of diverse benzodiazepines in microglia for cellular effects. Several active compounds were identified by reduction of nitric oxide (NO) in interferon gamma and lipopolysaccharide activated microglia. However, further investigation with GABAAR antagonists flumazenil, picrotoxin, and bicuculline demonstrated that GABAARs were not linked to the NO response. A screen of 48 receptors identified the κ-opioid receptor and to a lesser extent the μ-opioid receptor as molecular targets, with opioid receptor antagonist norbinaltorphimine reversing benzodiazepine induced reduction of microglial NO. Functional assays identified the downregulation of inducible NO synthase as the mode of action of imidazodiazepines MP-IV-010 and GL-IV-03. Like other κ-opioid receptor agonists, GL-IV-03 reduced the agitation response in both phases of the formalin nociception test. However, unlike other κ-opioid receptor agonists, MP-IV-010 and GL-IV-03 did not impair sensorimotor coordination in mice. Thus, MP-IV-010 and GL-IV-03 represent a new class of nonsedative drug candidates for inflammatory pain." @default.
- W3033762015 created "2020-06-12" @default.
- W3033762015 creator A5005438897 @default.
- W3033762015 creator A5011447670 @default.
- W3033762015 creator A5019210691 @default.
- W3033762015 creator A5020066977 @default.
- W3033762015 creator A5021570300 @default.
- W3033762015 creator A5028081311 @default.
- W3033762015 creator A5042400304 @default.
- W3033762015 creator A5048457363 @default.
- W3033762015 creator A5055005798 @default.
- W3033762015 creator A5056422210 @default.
- W3033762015 creator A5068573021 @default.
- W3033762015 creator A5074313840 @default.
- W3033762015 creator A5077888663 @default.
- W3033762015 creator A5089609052 @default.
- W3033762015 date "2020-06-08" @default.
- W3033762015 modified "2023-10-17" @default.
- W3033762015 title "Targeting Nitric Oxide Production in Microglia with Novel Imidazodiazepines for Nonsedative Pain Treatment" @default.
- W3033762015 cites W1859780204 @default.
- W3033762015 cites W1921896771 @default.
- W3033762015 cites W1965572881 @default.
- W3033762015 cites W1969307826 @default.
- W3033762015 cites W1973238622 @default.
- W3033762015 cites W1988239140 @default.
- W3033762015 cites W1988767853 @default.
- W3033762015 cites W1997023449 @default.
- W3033762015 cites W2001933690 @default.
- W3033762015 cites W2016560481 @default.
- W3033762015 cites W2026881175 @default.
- W3033762015 cites W2030194369 @default.
- W3033762015 cites W2034475831 @default.
- W3033762015 cites W2039352998 @default.
- W3033762015 cites W2044686423 @default.
- W3033762015 cites W2053710123 @default.
- W3033762015 cites W2058249192 @default.
- W3033762015 cites W2062077958 @default.
- W3033762015 cites W2080853291 @default.
- W3033762015 cites W2081340712 @default.
- W3033762015 cites W2092523142 @default.
- W3033762015 cites W2094408039 @default.
- W3033762015 cites W2110906442 @default.
- W3033762015 cites W2112374588 @default.
- W3033762015 cites W2116847572 @default.
- W3033762015 cites W2127649663 @default.
- W3033762015 cites W2127894556 @default.
- W3033762015 cites W2134557769 @default.
- W3033762015 cites W2137471600 @default.
- W3033762015 cites W2147804649 @default.
- W3033762015 cites W2163751922 @default.
- W3033762015 cites W2516962605 @default.
- W3033762015 cites W2552908886 @default.
- W3033762015 cites W2584799997 @default.
- W3033762015 cites W2586662902 @default.
- W3033762015 cites W2588526112 @default.
- W3033762015 cites W2606690637 @default.
- W3033762015 cites W2609533844 @default.
- W3033762015 cites W2613462571 @default.
- W3033762015 cites W2753593979 @default.
- W3033762015 cites W2791156006 @default.
- W3033762015 cites W4200337926 @default.
- W3033762015 cites W4238881352 @default.
- W3033762015 doi "https://doi.org/10.1021/acschemneuro.0c00324" @default.
- W3033762015 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7380323" @default.
- W3033762015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32511908" @default.
- W3033762015 hasPublicationYear "2020" @default.
- W3033762015 type Work @default.
- W3033762015 sameAs 3033762015 @default.
- W3033762015 citedByCount "5" @default.
- W3033762015 countsByYear W30337620152020 @default.
- W3033762015 countsByYear W30337620152022 @default.
- W3033762015 countsByYear W30337620152023 @default.
- W3033762015 crossrefType "journal-article" @default.
- W3033762015 hasAuthorship W3033762015A5005438897 @default.
- W3033762015 hasAuthorship W3033762015A5011447670 @default.
- W3033762015 hasAuthorship W3033762015A5019210691 @default.
- W3033762015 hasAuthorship W3033762015A5020066977 @default.
- W3033762015 hasAuthorship W3033762015A5021570300 @default.
- W3033762015 hasAuthorship W3033762015A5028081311 @default.
- W3033762015 hasAuthorship W3033762015A5042400304 @default.
- W3033762015 hasAuthorship W3033762015A5048457363 @default.
- W3033762015 hasAuthorship W3033762015A5055005798 @default.
- W3033762015 hasAuthorship W3033762015A5056422210 @default.
- W3033762015 hasAuthorship W3033762015A5068573021 @default.
- W3033762015 hasAuthorship W3033762015A5074313840 @default.
- W3033762015 hasAuthorship W3033762015A5077888663 @default.
- W3033762015 hasAuthorship W3033762015A5089609052 @default.
- W3033762015 hasBestOaLocation W30337620152 @default.
- W3033762015 hasConcept C126322002 @default.
- W3033762015 hasConcept C168258287 @default.
- W3033762015 hasConcept C169760540 @default.
- W3033762015 hasConcept C170493617 @default.
- W3033762015 hasConcept C178790620 @default.
- W3033762015 hasConcept C185592680 @default.
- W3033762015 hasConcept C2776914184 @default.
- W3033762015 hasConcept C2778409475 @default.
- W3033762015 hasConcept C2779177108 @default.
- W3033762015 hasConcept C2779324764 @default.